|[September 20, 2013]
New York Proton Consortium Expands Access to Proton Therapy Through Agreement with ProCure Proton Therapy Center in New Jersey
NEW YORK --(Business Wire)--
The New York Proton Center (NYPC) - a consortium of five leading
hospitals in New York City, including Continuum Health Partners,
Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, the
Mount Sinai Medical Center, and New York University Langone Medical
Center - today announced an agreement with ProCure Proton Therapy Center
in Somerset, NJ, CentraState Health Care System, Princeton Radiation
Oncology and management services for NYPC being provided by 21st
Century Oncology, a national provider of advanced radiation oncology
services. This agreement will give the consortium's patients access to a
state-of-the-art proton treatment center in Somerset, NJ, one of only
twelve such centers in the nation and the only center in the New York
and New Jersey region. Proton therapy is a unique form of precision
radiation that directly attacks tumors while minimizing potentially
damaging radiation to surrounding healthy tissues and organs.
The NYPC consortium noted in a brief statement that they are "deeply
committed to providing the highest standard of care to cancer patients,
which includes access to proton therapy. For certain patients,
especially those with solid tumors surrounded by sensitive tissue and
vital organs, proton therapy is often the treatment of choice."
Studies have shown proton therapy to be effective in treating many types
of tumors, including pediatric ancers and selected tumors of the head
and neck, brain, spinal cord, breast, gastrointestinal system, lung and
Unlike traditional x-ray beams that deposit a dose of radiation all the
way through the patient's body, proton beams stop abruptly and do not
deliver radiation dose beyond the tumor. In many cases, this unique
property of protons allows physicians to concentrate radiation within
the tumor while reducing the dose to surrounding tissues with greater
precision than can be achieved with conventional radiation beams,
thereby reducing the risk of side effects and improving the patient's
quality of life.
Recognizing these benefits of proton therapy for patients with specific
tumor types, NYPC's agreement with the ProCure Proton Therapy Center
allows this therapy to be conveniently accessible for their patients.
Under the agreement, patients receiving care at NYPC hospitals who need
proton therapy will continue to have their treatments provided by their
physicians who will now have treatment privileges at the Proton Center.
"It has always been the Mission of ProCure and our affiliate CentraState
Healthcare System to make proton therapy available to as many patients
as possible," said Dr. Oren Cahlon of Princeton Radiation Oncology,
Medical Director of the ProCure Proton Therapy Center in Somerset, NJ.
"Our agreement with NYPC allows us to share our access to proton therapy
and takes us one step closer to fulfilling our Mission."
The ProCure Proton Therapy Center in Somerset, NJ, in affiliation
with CentraState Healthcare System and Princeton Radiation Oncology,
opened in March 2012.
The New York Proton Therapy Center (NYPC) is an alliance of five
leading cancer treatment institutions in New York City and 21st
Century Oncology including Memorial Sloan-Kettering Cancer Center, New
York University Langone Medical Center, Montefiore Medical Center, the
Mount Sinai Medical Center, and Continuum Health Partners. The five
institutions include many of the premier cancer treatment institutions
in the world and together treat 19,000 new cancer patients every year.
Princeton Radiation Oncology (PRO) is the largest radiation
oncology practice in New Jersey and consists of 14 board-certified
radiation oncologists all who have trained at the best cancer programs
in the country, including Harvard Medical School, Memorial
Sloan-Kettering, University of Pennsylvania, Johns Hopkins, and MD
Anderson. PRO physicians are highly specialized in the most advanced
forms of radiation therapy, including proton therapy, and provide highly
compassionate, individualized care for all patients at six cancer
centers in New Jersey and Pennsylvania.
[ Back To Technology News's Homepage ]